Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 16
2001 19
2002 44
2003 49
2004 31
2005 39
2006 35
2007 43
2008 50
2009 45
2010 45
2011 43
2012 59
2013 48
2014 40
2015 29
2016 41
2017 33
2018 48
2019 53
2020 54
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

781 results
Results by year
Filters applied: . Clear all
Page 1
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Hills RK, et al. Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Lancet Oncol. 2014. PMID: 25008258 Free PMC article. Review.
BACKGROUND: Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia. ...These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licence status …
BACKGROUND: Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acu …
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
No differences in early death rate were observed between arms. The main toxicity associated with gemtuzumab ozogamicin was prolonged thrombocytopenia. Veno-occlusive disease (including after transplant) was observed in 6 patients in the gemtuzumab ozogamic
No differences in early death rate were observed between arms. The main toxicity associated with gemtuzumab ozogamicin was pro …
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J, Wang ES. Baron J, et al. Expert Rev Clin Pharmacol. 2018 Jun;11(6):549-559. doi: 10.1080/17512433.2018.1478725. Epub 2018 Jun 11. Expert Rev Clin Pharmacol. 2018. PMID: 29787320 Free PMC article. Review.
Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. ...
Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytoto
Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD, Gale RP, Walter RB. Godwin CD, et al. Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13. Leukemia. 2017. PMID: 28607471 Review.
CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in some. Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate d …
CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in s …
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
FINDINGS: 280 patients were randomly assigned to the control (n=140) and gemtuzumab ozogamicin groups (n=140), and 139 patients were analysed in each group. ...The findings warrant reassessment of gemtuzumab ozogamicin as front-line therapy for acute m …
FINDINGS: 280 patients were randomly assigned to the control (n=140) and gemtuzumab ozogamicin groups (n=140), and 139 patient …
Gemtuzumab Ozogamicin: Back Again.
Selby C, Yacko LR, Glode AE. Selby C, et al. J Adv Pract Oncol. 2019 Jan-Feb;10(1):68-82. Epub 2019 Jan 1. J Adv Pract Oncol. 2019. PMID: 31308990 Free PMC article. Review.
This regimen has undergone multiple modifications and patient performance status-based stratifications, but has remained the first-line therapy for AML for the past 45 years. In September 2017, gemtuzumab ozogamicin returned to market and shortly thereafter was adde …
This regimen has undergone multiple modifications and patient performance status-based stratifications, but has remained the first-line ther …
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.
Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C, Middleton G, Mussai F, De Santo C. Fultang L, et al. EBioMedicine. 2019 Sep;47:235-246. doi: 10.1016/j.ebiom.2019.08.025. Epub 2019 Aug 25. EBioMedicine. 2019. PMID: 31462392 Free PMC article.
The immunotoxin Gemtuzumab ozogamicin can deplete MDSCs providing a translational approach to reactivate T cell and CAR-T cell responses against multiple cancers. In the rare conditions of HLH/MAS gemtuzumab ozogamicin provides a novel anti-myeloid str …
The immunotoxin Gemtuzumab ozogamicin can deplete MDSCs providing a translational approach to reactivate T cell and CAR-T cell …
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group.
Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M. Niktoreh N, et al. Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9. Haematologica. 2019. PMID: 30093401 Free PMC article. Clinical Trial.
At doses of 2.5-10 mg/m(2), gemtuzumab ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabine (47%), or others (6%). ...Probability of 4-year overall survival was 185% in all, 277% in patients with and 0% in patients without hemato …
At doses of 2.5-10 mg/m(2), gemtuzumab ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabi …
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M, Sperotto A, Ghelli Luserna Di Rorà A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, Cerchione C. Gottardi M, et al. Minerva Med. 2020 Oct;111(5):395-410. doi: 10.23736/S0026-4806.20.07019-6. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955828 Free article. Review.
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33<sup>+</sup> acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab o
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refrac …
Gemtuzumab Ozogamicin.
[No authors listed] [No authors listed] 2018 Mar 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643757 Free Books & Documents. Review.
Gemtuzumab ozogamicin is a humanized monoclonal antibody conjugate which is used in the therapy of acute myelogenous leukemia. Gemtuzumab ozogamicin has been linked to transient serum enzyme elevations during therapy and not uncommon instances of acute
Gemtuzumab ozogamicin is a humanized monoclonal antibody conjugate which is used in the therapy of acute myelogenous leukemia.
781 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page